GlassScriptPhysician profile
James J Dearing
NPI 1528065422
$1,109.64
in general payments reported to CMS, 2019-2025
25 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.94 · 2020: $290 · 2021: $292 · 2022: $186 · 2023: $178 · 2024: $45.80 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $330.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $156.10 | 2022-2025 | Breztri, Airsupra |
| Boston Scientific Corporation | $134.50 | 2020-2025 | General - Vascular Intervention |
| Edwards Lifesciences Corporation | $119.60 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.23 | 2019-2022 | |
| Lucid Diagnostics INC. | $95.80 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.30 | 2020-2021 | |
| Abbott Laboratories | $41.68 | 2022 | |
| Medtronic, INC. | $38.63 | 2023-2025 | Intellis Adaptivestim |
| Nevro Corp. | $36.46 | 2021-2024 | Senza |
| Axonics, INC. | $33.34 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $32.93 | 2021-2022 | |
| Astellas Pharma US INC | $23.76 | 2022 | |
| Coopersurgical, INC. | $22.21 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.05 | 2021 | |
| Exact Sciences Corporation | $19.45 | 2025 | Cologuard Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $18.71 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.23 | 2023 | Jardiance |
| Glaxosmithkline, LLC. | $17.75 | 2023 | Shingrix |
| Smith+Nephew, INC. | $17.27 | 2023 | Pico 7, Renasys Go V2 Home |
| Abbvie INC. | $15.64 | 2021 | |
| Novo Nordisk INC | $15.27 | 2023 | Ozempic, Rybelsus |
| Noven Therapeutics, LLC | $14.77 | 2025 | Xelstrym |
| Medtronic USA, INC. | $14.29 | 2020 | |
| Exeltis, USA INC. | $13.92 | 2021 | |
| Sonex Health, INC. | $12.75 | 2025 | Sx-One Microknife |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Dearing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.